Lates News

Citic Securities Research Report indicates that the innovative nuclear medicine RDC is expected to address the unsatisfied clinical needs in the diagnosis and treatment process of prostate cancer, such as the large burden of detection and limited efficacy, and change the paradigm of prostate cancer diagnosis and treatment, realizing integrated diagnosis and treatment, improving patient compliance and survival. Currently, there is no RDC listed in the Chinese market, presenting a blue ocean state. Overseas prostate cancer RDC diagnosis and treatment products are expected to enter the market in 2021 and approach a market size of nearly 3 billion USD by 2024, fully validating its enormous commercial value. We believe China is likely to replicate the development path of overseas prostate cancer RDC diagnosis and treatment market and predict that the future Chinese market for prostate cancer RDC diagnosis and treatment will exceed 10 billion RMB, showing a rapid growth trend. We believe that the key points in this industry are isotopes, ligand molecular forms, and production and distribution capabilities, and we recommend focusing on companies that have advantages in these conditions.